Rising Prevalence Of Inflammatory Bowel Disorders Drives Growth Of Crohn's Disease Treatment Market Driver: A Major Catalyst in the Evolution of the Crohn's Disease Treatment Market in 2025

What industry-specific factors are fueling the growth of the crohn's disease treatment market?
The observed surge in inflammatory bowel disorders is anticipated to trigger an upward trajectory in the Crohn's disease treatment market. These disorders encompass a set of enduring conditions associated with inflammation in the gastrointestinal tract, leading to potential inflammation or damage to any section of the digestive system, from oral cavity to the rectum*. Treatment of Crohn's disease primarily aims to reduce the inflammation within the intestines, stave off symptoms flare-ups, and maintain remission. To illustrate, the National Center for Biotechnology Information, a government agency based in the US, reported in September 2023 that there has been a similar surge in the prevalence of Crohn's disease and ulcerative colitis. Inflammatory bowel disease is projected to affect 825 in every 100,000 people in 2023, with 410 cases attributed to Crohn's disease and 414 to ulcerative colitis and IBD-u. Consequently, the escalating rates of these disorders are serving as a catalyst to the growth of the Crohn's disease treatment market.

Get Your Crohn's Disease Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

What Is the projected market size and growth rate for the crohn's disease treatment market?
Over the recent years, the market size for Crohn's disease treatment has seen significant growth. It's predicted to expand from $12.45 billion in 2024 to $13.23 billion in 2025, marking a compound annual growth rate (CAGR) of 6.2%. Factors contributing to this growth during the historical period include increased prevalence of the disease, improved diagnostic approaches, adoption of biological therapies, patient awareness and education, alongside clinical research and development.

The market size for Crohn's disease treatment is anticipated to experience significant expansion in the coming years, with projections indicating it will reach "$17.67 billion by 2029, growing at a compounded annual growth rate (CAGR) of 7.5%. This projected growth within the forecast period can be traced back to factors such as the adoption of personalized medicine, expansion in the biologics market, updates to treatment guidelines, increased funding in healthcare, as well as concerted research initiatives. Key trends that are expected to emerge during the forecast period feature the utilization of telemedicine for patient supervision, exploration of immune modulation methods, adoption of patient-focused care systems, and the integration of digital healthcare solutions.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10852&type=smp

What new trends are reshaping the crohn's disease treatment market and its opportunities?
Leading businesses in the Crohn's disease therapy industry are devising new medication, such as the biosimilar ustekinumab, and obtaining approval for their use, with the aim of improving the accessibility and effectiveness of treatment pathways for patients, thereby enhancing their health outcomes and overall wellbeing. The term biosimilar ustekinumab describes a biological drug that closely resembles the original ustekinumab (a type of monoclonal antibody) utilised in the treatment of autoimmune diseases. Notably, in July 2024, Pyzchiva (ustekinumab) was released across Europe by the Switzerland-based pharmaceutical firm, Sandoz International GmbH. This marked the first instance of a ustekinumab biosimilar being made accessible in every strength, including a 130 mg vial designed specifically for Crohn's disease treatment. The product is indicated for adults and kids aged over six suffering from plaque psoriasis, psoriatic arthritis, and Crohn's disease. This move is a significant addition to Sandoz's immunology portfolio, and aims at enhancing the availability of cost-effective remedies for chronic inflammatory ailments.

What major market segments define the scope and growth of the crohn's disease treatment market?
The crohn's disease treatment market covered in this report is segmented -

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications

Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics
2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates
3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids
4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine
5) By Other Drug Types: Biologics, Small Molecules, Other Treatments

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10852

Which region dominates the crohn's disease treatment market?
North America was the largest region in the global Crohn's disease treatment market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the Crohn's disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the crohn's disease treatment industry growth?
Major companies operating in the crohn's disease treatment market include AbbVie Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Bristol-Myers Squibb Company, Galapagos NV, Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Arena Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10852&type=smp

What Is Covered In The Crohn's Disease Treatment Global Market Report?

• Market Size Forecast: Examine the crohn's disease treatment market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the crohn's disease treatment market for a structured understanding.
• Key Players Overview: Analyze major players in the crohn's disease treatment market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the crohn's disease treatment market.
• Segment Contributions: Evaluate how different segments drive overall growth in the crohn's disease treatment market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the crohn's disease treatment market.
• Industry Challenges: Identify potential risks and obstacles affecting the crohn's disease treatment market.
• Competitive Landscape: Review strategic developments in the crohn's disease treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.